title: Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
authors.forename: Costas
authors.initials: C
authors.lastname: Tsatalas
authors.forename: Dimitris
authors.initials: D
authors.lastname: Margaritis
authors.forename: Despina
authors.initials: D
authors.lastname: Pantelidou
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Spanudakis
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Kaloutsi
authors.forename: George
authors.initials: G
authors.lastname: Bourikas
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006942:Hypergammaglobulinemia; D007119:Immunoblastic Lymphadenopathy / Q000150:complications* / Q000188:drug therapy*; D016399:Lymphoma, T-Cell / Q000150:complications* / Q000188:drug therapy*; D008875:Middle Aged; D012074:Remission Induction; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine